Values of serum tumor necrosis factor-α stimulated gene 6 protein and type ⅩⅥ collagen in predicting prognosis of patients with ulcerative colitis
- VernacularTitle:血清肿瘤坏死因子α刺激基因6蛋白和ⅩⅥ型胶原蛋白预测溃疡性结肠炎患者预后的价值
- Author:
Lijun MENG
1
;
Lanfang ZHANG
;
Lei QIN
;
Wenjing LI
;
Peijun SHEN
;
Xu CHEN
;
Xiaohe GUO
Author Information
- Publication Type:Research Article
- Keywords: tumor necrosis factor-α stimulated gene 6 protein; type ⅩⅥ collagen; ulcerative colitis; prognosis; correlation; predictive value
- From: Journal of Clinical Medicine in Practice 2024;28(23):87-90
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the values of serum tumor necrosis factor-α stimulated gene 6 protein (TSG-6) and type ⅩⅥ collagen (col-16) in predicting the prognosis of patients with ulcerative colitis (UC). Methods A total of 160 patients with UC were enrolled as UC group, another 160 volunteers were selected as control group, and the levels of serum TSG-6 and col-16 were compared between the two groups. According to the modified Mayo scoring criteria, patients in the UC group were divided into mild group (
n =63), moderate group (n =52), and severe group (n =45), and the levels of serum TSG-6 and col-16 were compared among the three groups. Based on the colonoscopy follow-up results, patients in the UC group were divided into good prognosis group (n =121) and poor prognosis group (n =39), and the levels of serum TSG-6 and col-16 were compared between the two groups. Spearman correlation analysis was used to explore the correlations of serum TSG-6 and col-16 with the modified Mayo score. Logistic regression analysis was used to investigate the impact of serum TSG-6 and col-16 on the prognosis of patients in the UC group. Receiver operating characteristic (ROC) curve was used to assess the values of serum TSG-6 and col-16 in predicting the prognosis of patients in the UC group. Results The levels of serum TSG-6 and col-16 in the UC group were significantly higher than those in the control group (P < 0.01). The levels of serum TSG-6 and col-16 in the moderate and severe groups were significantly higher than those in the mild group, and the levels of serum TSG-6 and col-16 in the severe group were significantly higher than those in the moderate group (P < 0.01). The levels of serum TSG-6 and col-16 in the poor prognosis group were significantly higher than those in the good prognosis group (P < 0.01). Spearman correlation analysis showedthat serum TSG-6 and col-16 were positively correlated with the modified Mayo score (r =0.691,P < 0.05;r =0.635,P < 0.05). Logistic analysis results showed that serum TSG-6 and col-16 were risk factors for poor prognosis (P < 0.001). ROC curve analysis showed that the areas under the curve for predicting poor prognosis in patients with UC were 0.773 and 0.765 for serum TSG-6 and col-16, respectively. Conclusion The levels of serum TSG-6 and col-16 are abnormally elevated in patients with UC, and there is a certain correlation of the two indexes with the severity and prognosis of disease, and the two indexes can be used as predictors of poor prognosis.
